๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma
NCT06070740Gastrointestinal Neuroendocrine Carcinoma
Peking Union Medical College Hospital
Phase 2
22
Beijing
2023-11-01
Recruiting
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
NCT06139042Liver Cancer, Biliary Tract Cancer, Pancreatic Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,608
Hangzhou
2023-11-01
Recruiting
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
NCT06141265Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
116
Beijing
2023-11-01
Recruiting
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
NCT06121557Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
24
Guangzhou
2023-11-01
Not yet open
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
NCT06089382Hepatocellular Carcinoma
Tongji Hospital
Phase 3
104
Wuhan
2023-11-01
Recruiting
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
NCT06093438Cervical Cancer, Induction Chemotherapy, Immunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2
20
Tianjin
2023-11-01
Recruiting
The Influence of Nutritional Factors on the Prognosis of Liver Cirrhosis Patients and the Exploration of Predictive Models
NCT06328517Cirrhosis
Juan Kang
Observational
300
Chongqing
2023-11-01
Recruiting
Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naรฏve Ph+ Acute Lymphoblastic Leukemia
NCT06082934Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
Xijing Hospital
Phase 1/2
30
Xi'an
2023-11-01
Recruiting
Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia
NCT06137196AIDS, Pneumonia
Guangzhou 8th People's Hospital
Observational
100
Guangzhou
2023-11-01
Recruiting
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
NCT06095089Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
355
Wenzhou
2023-11-01
Active, closed
Distinguishing Retroperitoneal Fibrosis and Sarcoma from Other Retroperitoneal Diseases Via Radiomics
NCT06741423Retroperitoneal Sarcoma, Retroperitoneal Fibrosis
Heidelberg University
Observational
600
Beijing
2023-11-01
Recruiting
Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06107582Primary Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Observational
500
Tianjin
2023-11-01
Recruiting
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
NCT06066203Non-hodgkin's Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
40
Beijing
2023-11-01
Recruiting
Multi-center Study on Comprehensive Diagnosis and Treatment of Lower Limb Bone Defect Based on Three-dimensional Printing Technology
NCT06269354Bone Defects
Peking University Third Hospital
Observational
120
Beijing
2023-11-01
Recruiting
Pan-Amyloid PET/CT in Various Amyloid-Related Disease
NCT07130565Amyloid, Cardiac Amyloidosis, Amyloidosis
Tianjin Medical University
Observational
500
Hefei, Qingdao, Tianjin
2023-11-01
Recruiting
Assessment System of Sarcopenia in Lung Cancer Patients
NCT06327594Sarcopenia, Lung Cancer, Ultrasound
West China Hospital
Observational
1,500
Chengdu
2023-11-01
Recruiting
The Effect of Aspirin on Recurrent Acute Pancreatitis
NCT06185621Recurrent Acute Pancreatitis, Prevention, Aspirin
Air Force Military Medical University, China
Not applicable
23
Xi'an
2023-11-01
Recruiting
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
NCT06017284Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
Fudan University
Phase 3
100
Shanghai
2023-11-01
Active, closed
PET-CT Predicting Lymph Nodes Metastasis
NCT05970913Non Small Cell Lung Cancer, Lymph Node Metastasis, Positron Emission Tomography
Fudan University
Observational
280
Shanghai
2023-11-01
Recruiting
Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
NCT06688760Nasopharyngeal Carcinoma, Surgery, Radiotherapy
Ming-Yuan Chen
Not applicable
86
Guangzhou, Zhuhai
2023-11-01
Recruiting
PPG vs. ICG in Gastrointestinal Resections
NCT06222645Anastomosis, Perfusion, Postoperative Complications, Gastrointestinal Neoplasms
Saint Petersburg State University, Russia
Not applicable
200
Yantai
2023-11-01
Recruiting
Oriental Intervention for Enhanced Neurocognitive Health (Orient) Diet in Populations With High Risk of Stroke (ENDS)
NCT06098235High Risk of Stroke
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
160
Hangzhou
2023-11-01
Recruiting
TDCS Interventions for Subthreshold Depressive Symptoms in Young Individuals.
NCT06294184Subthreshold Depression, Young People, Transcranial Direct Current Stimulation
Guangzhou Psychiatric Hospital
Not applicable
150
Guangzhou
2023-11-01
Recruiting
Effect and Mechanism of Brain Stimulation for Parkinson's Disease With Cognitive Impairment
NCT06090682Parkinson Disease, Cognitive Impairment
Tianjin Huanhu Hospital
Observational
200
Tianjin
2023-11-01
Recruiting
Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis
NCT06095596Ulcerative Colitis (UC)
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
334
Guangzhou
2023-11-01
Recruiting
Real-world Evaluation of Qingxin Zishen Decoction on Ovarian Reserve Function Clinical Efficacy in Patients With Decreased
NCT06332742Decreased Ovarian Reserve
Yun Chen
Observational
178
Nanjing
2023-11-01
Not yet open
A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer
NCT06039982Cervix Carcinoma
Fujian Cancer Hospital
Observational
100
Fuzhou
2023-11-01
By invitation
Positron Emission Tomography in Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depression
NCT06044324Treatment Resistant Depression, Visual Perceptual Weakness
First Affiliated Hospital of Zhejiang University
Not applicable
42
Hangzhou
2023-11-01
Recruiting
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
NCT05952947Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
HRYZ Biotech Co.
Phase 1
32
Shanghai
2023-11-01
Active, closed
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT06057610HER2-PositiveRecurrent or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
868
Nanjing
2023-11-01
Recruiting
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
NCT06154538Locally Advanced Colorectal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
170
Beijing, Guangzhou, Jinan
2023-11-01
Recruiting
A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
NCT06001086Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
70
Nanjing
2023-11-01
Not yet open
Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism
NCT05947162Tobacco Use Disorder
Shenzhen Kangning Hospital
Not applicable
150
Shenzhen
2023-11-01
Recruiting
Surveillance for Multifocal GGNs
NCT06097910Lung Ground-glass Opacities, Active Surveillance
Fudan University
Observational
370
Shanghai
2023-11-01
Recruiting
Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
NCT06221722Constipation - Functional, Refractory Constipation, Fluoxetine, fMRI
Xijing Hospital of Digestive Diseases
Observational
150
Yinchuan, Xi'an
2023-11-01
Not yet open
Radial Artery Versus No-touch Saphenous Vein
NCT06014047Coronary Artery Disease
China National Center for Cardiovascular Diseases
Not applicable
774
Beijing
2023-11-01
Recruiting
Clinical Research on the Treatment Model of Ambulatory Surgery for Colorectal Cancer
NCT06637215Colorectal Carcinoma, Day Surgery
First Hospital of China Medical University
Not applicable
352
Shenyang
2023-11-01
Recruiting
Head Acupuncture Treat Residual Symptoms After Canalith Repositioning Procedure for BPPV
NCT06001047Benign Paroxysmal Positional Vertigo
Xi'an No.3 Hospital
Not applicable
120
Xi'an
2023-11-01
Recruiting
TBI/Flu/Bu/Mel Combined With Secondary UCBT in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT
NCT06125483Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation
The First Affiliated Hospital of Soochow University
Not applicable
38
Suzhou
2023-11-01
Recruiting
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized๏ผŒOpen-label Clinical Trial.
NCT06079788Nephrotic Syndrome in Children
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Recruiting
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
NCT05891561Breast Cancer
Shanghai Jiao Tong University School of Medicine
Phase 2
120
Shanghai
2023-11-01
Recruiting
Ischemic Post-conditioning in Acute Ischemic Stroke Thrombectomy (PROTECT-2)
NCT05789823Acute Ischemic Stroke
Capital Medical University
Phase 2
160
Tianjin
2023-11-01
Recruiting
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
NCT06485271Gastric Cancer, RWS, PD-1 Immunotherapy
Changzhi People's Hospital Affiliated to Changzhi Medical College
Observational
504
Changzhi
2023-11-01
Active, closed
Efficacy and Safety of TTM in Adults With ECPR.
NCT06608095Cardiac Arrest
Peking University Third Hospital
Not applicable
146
Beijing
2023-11-01
Recruiting
Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program
NCT07270419Aneurysmal Subarachnoid Hemorrhage
Xiaolin Chen, MD
Observational
2,000
Beijing
2023-11-01
Recruiting
Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer
NCT07504523Metastatic Colorectal Cancer (CRC)
Ying Yuan, MD
Phase 1
20
Hangzhou
2023-11-01
By invitation
Cardiovascular Imaging in Pediatric Myocarditis
NCT06652399Myocarditis
West China Second University Hospital
Observational
100
Chengdu
2023-11-01
Not yet open
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
NCT06118658Gastric, Colorectal Adenocarcinoma
China Medical University, China
Phase 2
30
Shenyang
2023-11-01
Not yet open
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
NCT06134531Advanced Solid Tumors
Nanfang Hospital, Southern Medical University
Phase 1
31
Guangzhou
2023-11
Not yet open
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
NCT06102161Lung Cancer, Wedge Resection, Ground-glass Opacity
Fudan University
Phase 3
286
Shanghai
2023-11
Recruiting
Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN
NCT05842109ABO Hemolytic Disease of Newborn
Women's Hospital School Of Medicine Zhejiang University
Observational
112
Hangzhou
2023-10-31
Active, closed
Observational, Bivariate Analysis of Clinical Big Data in Patients With Cervical Cancer
NCT06480617Progression-free Survival Was Defined From Date of Surgery to Disease Progression Post-surgery or Death or Last Follow-up, Overall Survival Was Defined as Time From Surgery to Death From Any Cause or Last Follow-up
Anhui Provincial Hospital
Observational
3,000
Hefei
2023-10-31
Recruiting
Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma
NCT06017895Swallowing-induced Pain
Nanfang Hospital, Southern Medical University
Not applicable
178
Guangzhou
2023-10-31
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626Metastatic Breast Cancer
LeonaBio
Phase 3
600
Anhui, Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqicun
2023-10-31
Recruiting
App and Body Fat Scale in the Management of Overweight Patients
NCT05866107Schizophrenia, Bipolar Disorder, Metabolic Syndrome, Overweight and Obesity
Capital Medical University
Not applicable
204
Beijing
2023-10-31
Recruiting
Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)
NCT05906953Leber Congenital Amaurosis, Inherited Retinal Diseases Caused by RPE65 Mutations
HuidaGene Therapeutics Co., Ltd.
Phase 1/2
20
Shanghai
2023-10-31
Recruiting
Study of TRX-920 for Patients With Advanced Solid Tumors
NCT06143774Advanced Solid Tumor
TaiRx, Inc.
Phase 1
30
2023-10-31
Active, closed
Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus
NCT05749874PreDiabetes, Abdominal Obesity, Hypertension, Dyslipidemias
China National Center for Cardiovascular Diseases
Phase 4
2,024
Beijing
2023-10-31
Recruiting
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
NCT06081959Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
376
Beijing
2023-10-31
Recruiting
The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI
NCT06304779Postoperative Pulmonary Complications, Intra-abdominal Infection
Shanghai Zhongshan Hospital
Not applicable
428
Shanghai
2023-10-31
Recruiting
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
NCT06041477Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
Sun Yat-sen University
Phase 3
540
Guangzhou
2023-10-31
Active, closed
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
NCT06031558Non-Small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD
Phase 3
120
Shanghai
2023-10-31
Recruiting
Anti-inflammatory Therapy for Recurrent In-stent Restenosis
NCT06090890In-stent Restenosis
Fu Wai Hospital, Beijing, China
Phase 4
252
Beijing
2023-10-30
Active, closed
A Study of SI-B001+SI-B003ยฑ Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT05949606Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
95
Shanghai
2023-10-30
Recruiting
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
NCT06102928Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Kunming Medical University
Not applicable
30
Kunming
2023-10-30
Recruiting
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
NCT06098560Colorectal Cancer
Geneplus-Beijing Co. Ltd.
Observational
60
Beijing, Shanghai
2023-10-30
Active, closed
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
NCT05879822Advanced Solid Tumor
Incyte Corporation
Phase 2
73
Nanning
2023-10-30
Recruiting
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
NCT06081673Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
72
Shanghai
2023-10-30
Recruiting
IN10018 Combination Therapy in Treatment-naรฏve ES-SCLC
NCT06030258Small Cell Lung Cancer Extensive Stage
InxMed (Shanghai) Co., Ltd.
Phase 1/2
120
Jinan, Tianjin, Zhengzhou
2023-10-30
Recruiting
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
NCT06399926Leptomeningeal Metastasis, Lung Cancer
Xiangya Hospital of Central South University
Observational
64
Changsha
2023-10-30
Not yet open
Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
NCT06062641Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital
Phase 2
50
Shanghai
2023-10-30
Recruiting
Clinical Characteristics and Prognosis of Aortic Dissection in China (CLASSIC)
NCT05999188Aortic Dissection
First Affiliated Hospital Xi'an Jiaotong University
Observational
100
Xi'an
2023-10-30
Recruiting
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
NCT06190067Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Navy General Hospital, Beijing
Phase 2
40
Beijing
2023-10-30
Recruiting
The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.
NCT06477991Clinical Complete Response Rate With Negative MRD
Yunnan Cancer Hospital
Observational
22
Kunming
2023-10-30
Recruiting
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ๏ผšSingle-arm, Prospective, Open Clinical Study
NCT06125080TNBC - Triple-Negative Breast Cancer
Huihua Xiong
Phase 2
78
Wuhan
2023-10-30
Not yet open
A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
NCT06077305Cerebral Small Vessel Diseases, Ischemic Stroke
Beijing Tiantan Hospital
Observational
20,000
Beijing
2023-10-30
Recruiting
Registration Trial of the Intracranial Visualized Stent for the Wide-necked Intracranial Aneurysms:REBRIDGE
NCT06189950Brain Diseases, Aneurysm, Intracranial Aneurysm
MicroPort NeuroTech Co., Ltd.
Not applicable
200
Zhengzhou
2023-10-30
Recruiting
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
NCT06125041Extensive Small Cell Lung Cancer
Qianfoshan Hospital
Phase 2
51
Jinan
2023-10-30
Recruiting
Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients
NCT06257043Aortic Valve Disease Mixed
Xijing Hospital
Observational
3,000
Xi'an
2023-10-30
Active, closed
XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
NCT06147505Tumor
Dushu Lake Hospital Affiliated to Soochow University
Phase 1/2
13
Suzhou
2023-10-29
Recruiting
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
NCT06125847Homozygous Familial Hypercholesterolemia
First Affiliated Hospital Xi'an Jiaotong University
Phase EARLY_PHASE1
21
Xi'an
2023-10-29
Recruiting
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT05978284Small Cell Lung Cancer, Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
54
Zhengzhou
2023-10-27
Recruiting
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
NCT06008288KRAS P.G12C, Pancreatic Cancer, Solid Tumor
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Recruiting
Preventive Effect of Probiotics in GDM
NCT06938464Gestational Diabetes Mellitus (GDM)
Women's Hospital School Of Medicine Zhejiang University
Not applicable
334
Hangzhou
2023-10-27
Active, closed
Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers
NCT06105151Schizophrenia
Vigonvita Life Sciences
Phase 1
82
Beijing
2023-10-27
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
Novartis Pharmaceuticals
Phase 3
612
Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang
2023-10-27
Recruiting
A Study of Chidamide With AZA in MRD Positive AML After Transplant
NCT06066905AML, Adult, Minimal Residual Disease
Guangdong Provincial People's Hospital
Not applicable
60
Guangzhou
2023-10-26
Active, closed
A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
NCT06143007Advanced Solid Tumor
Broadenbio Ltd., Co.
Phase 1
42
Beijing
2023-10-26
Recruiting
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
NCT06247605Small Cell Lung Carcinoma
Advenchen Laboratories Nanjing Ltd.
Phase 3
243
Changchun
2023-10-26
Recruiting
Study on c-Met Targeted PET/CT Imaging in NSCLC
NCT06911697PET/CT Imaging, NSCLC
Xilin Sun
Not applicable
88
Harbin
2023-10-26
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
Summit Therapeutics
Phase 3
1,600
Yangzhou, Tongzhou, Fuzhou, Lanzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-10-26
Recruiting
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
NCT06182696Relapsed and/or Refractory Multiple Myeloma
OriCell Therapeutics Co., Ltd.
Phase 1/2
83
Hangzhou, Beijing, Nanjing, Shanghai, Wuhan
2023-10-26
Recruiting
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University
Observational
100
Hangzhou
2023-10-26
Recruiting
Characteristics of Cardiac Tumor and the Risk Stratification of Subsequent Adverse Events (UNIQUE)
NCT06100328Cardiac Tumor
First Affiliated Hospital Xi'an Jiaotong University
Observational
40
Xi'an
2023-10-26
Recruiting
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
NCT05985109Colorectal Cancer
Peking University Cancer Hospital & Institute
Phase 2
98
Beijing
2023-10-26
Recruiting
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
NCT06225856Advanced Solid Tumor, Hematological Malignancy
Shanghai Yuyao Biotech Co., Ltd.
Phase 1
96
Shanghai
2023-10-26
Recruiting
Routine Angiography Follow-Up After Percutaneous Coronary Intervention in High-Risk Patients
NCT05923489Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
2,618
Hangzhou
2023-10-26
Recruiting
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
NCT06008119Colorectal Cancer Metastatic
Shanghai Kechow Pharma, Inc.
Phase 3
165
Beijing
2023-10-25
Recruiting
Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension
NCT07604805Idiopathic Pulmonary Hypertension
Guangdong Provincial People's Hospital
Not applicable
120
Guangzhou
2023-10-25
Recruiting
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study
NCT06091423Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Xiaofeng Chen
Phase 2
43
Nanjin
2023-10-25
Rows per page Showing 14401–14500 of 19052
Previous 143 144 145 146 147 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=145

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.